Harmony Biosciences (HRMY) reported Q2 EPS of $0.57, $0.09 better than the analyst estimate of $0.48. Revenue for the quarter came in at $107 million versus the consensus estimate of $100.73 million.
Harmony Biosciences (HRMY) reported Q2 EPS of $0.57, $0.09 better than the analyst estimate of $0.48. Revenue for the quarter came in at $107 million versus the consensus estimate of $100.73 million.